Glenmark Announces the Discovery of a Novel Chemical Entity 'GRC 17536', a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally

With This Announcement, Glenmark has Clearly Reaffirmed its Position Globally as the Leader in the TRP Space

MUMBAI, India, August 31, 2010 - Glenmark Pharmaceuticals today announced the discovery of a
Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting
TRPA1 receptor antagonists for pain and respiratory disorders. TRPA1 belongs
to Transient Receptor Potential (TRP) family of ion channels, which have
generated a lot of interest as pain targets due to their distinguishing role
in peripheral and/or central pain signal transmission.

Glenmark has selected a lead molecule named GRC 17536 which is
currently finishing up Phase 1 enabling GLP studies. Preclinical studies have
been completed and Glenmark plans to file the Phase 1 application in January
2011. This is another potential first-in-class molecule globally for Glenmark

Commenting on this discovery, Glenn Saldanha, CEO & MD,
Glenmark Pharmaceuticals ltd mentioned " Both our earlier TRP molecules i.e.
TRPV1 and TRPV3 resulted in outlicensing deals for the company. GRC 17536
which is a TRPA1 receptor antagonist is another potential first-in-class
globally and we are encouraged by the results shown by the molecule in animal
studies. GRC 17536 is highly selective even when compared with other TRPs and
can be administered orally"

Glenmark is now positioned as one of the leading companies
engaged in the discovery of novel TRP antagonists. Previously Glenmark has
worked on TRPV1 and TRPV3 receptors and was able to successfully bring
programs into clinical development. Both of these programs also resulted in
out-licensing deals for Glenmark.

GRC 17536, which is Glenmark's lead is a highly potent (<
10nM) TRPA1 antagonist, which is highly selective (> 1000 fold over other
TRPs) and orally available. It has proven highly efficacious in treating
inflammatory and neuropathic pain in animal models compared to gold standard
drugs. It reversed hyperalgesia in vivo models of Freund's complete adjuvant
- induced inflammatory and chronic constriction injury (CCI) - induced
neuropathic pain with an EC50 of less than 10 mg/kg. In addition, when tested
in an in vivo model of asthma, it showed promising effect on airway
inflammation, bronchoconstriction and cough. So far, the compound has showed
good safety in the safety pharmacology and toxicology studies performed till
date.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven,
global, integrated pharmaceutical company headquartered at Mumbai, India. It
is a leading player in the discovery of new molecules both NCEs (new chemical
entity) and NBEs (new biological entity). The company has a significant
presence in branded generics markets across emerging economies including
India.

    For further information, please contact:
    Jason D'Souza
    Glenmark, Mumbai, India
    Tel: +91-22-40189919
    Email: media@glenmarkpharma.com

For further information, please contact: Jason D'Souza, Glenmark, Mumbai, India, Tel: +91-22-40189919, Email: media at glenmarkpharma.com